Corporate Profile
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Through its pipeline agents, the Company is determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.
Day High
Day Low
Volume
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Press Releases
Recent Events
Syndax Second Quarter 2024 Conference Call
08.01.24 / 4:30 PM EDT
Goldman Sachs 45th Annual Global Healthcare Conference
06.12.24 / 8:40 AM EDT
Bank of America Securities 2024 Health Care Conference
05.16.24 / 11:00 AM EDT